

Characterization of *Staphylococcus Aureus* Carriage Among Asymptomatic Individuals in the Republic of Congo

Claujens Chastel Mfoutou Mapanguy^{1,2}, Jealvie Narcia Limingui^{1,2}, Frieder Schaumburg³, Linzy Elton⁴, Euphra Dareine Bitoumbou^{1,2}, Jeannhey Christevy Vouvougui^{1,2}, Nick Desy Mouhingou^{1,2}, Kamal Boumpoutou¹, Alain Maxime Mouanga^{1,5}, Raoul Ampa², Thirumalaisamy P Velavan⁶, Alimuddin Zumla^{4,7}, Timothy D McHugh⁴ and Francine Ntoumi^{1,6*}

¹Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo

²Faculty of Sciences and Techniques, Marien Ngouabi University, Brazzaville, Republic of Congo

³Institutes of Medical Microbiology, University Hospital Münster, Münster, Germany

⁴Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, United Kingdom

⁵Faculté des sciences de la santé, University Marien Ngouabi, Brazzaville, Republic of Congo

⁶Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

⁷National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom

***Corresponding Author:** Francine Ntoumi, Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo, E-mail: fntoumi@fcrm-congo.com

Received Date: November 10, 2024 **Accepted Date:** December 10, 2024 **Published Date:** December 13, 2024

Citation: Claujens Chastel Mfoutou Mapanguy, Jealvie Narcia Limingui, Frieder Schaumburg, Linzy Elton, Euphra Dareine Bitoumbou, et al. (2024) Characterization of *Staphylococcus Aureus* Carriage Among Asymptomatic Individuals in the Republic of Congo. J Antibiot Antimicrob Agents 1: 1-12

Abstract

Introduction: *Staphylococcus aureus* is a significant contributor to bacterial-related mortality globally, often stemming from pre-existing asymptomatic colonization, including strains resistant to antibiotics. Despite its importance, data on *S. aureus* colonization and asymptomatic carriage remains limited in some African region. Here, we conducted a cross-sectional study to assess *S. aureus* carriage among healthy adults in the Republic of Congo, while also investigating molecular markers of antimicrobial resistance.

Methods: Healthy adult volunteers residing in Brazzaville were recruited at the Centre de Recherche sur les Maladies Infectieuses Christophe Mérieux (CeRMI-CM) of the Fondation Congolaise pour la Recherche Médicale (FCRM). After informed consent, nasal and oropharyngeal swabs were collected and processed using standard microbiological procedures to

isolate *S. aureus*. Antimicrobial susceptibility testing was carried out by disc diffusion, with confirmation of Methicillin resistance and Panton-Valentine Leukocidin (PVL) by PCR.

Results: Among 175 adults examined, 39 (22%) were colonized with *S. aureus*. Of these, 29/39 (74%) were nasal carriers, 6/39 (15%) were oropharyngeal carriers and 4/39 (10%) were dual carriers. Methicillin-resistant *S. aureus* (MRSA) was detected in 4/39 (10%) of asymptomatic individuals. Among all isolates, 9/39 (23%) were positive for PVL (2 MRSA, 7 methicillin-susceptible *S. aureus* [MSSA]). Resistance to other antibiotics was prevalent among MSSA strains, notably Azithromycin and Erythromycin resistance rates of 21% each.

Conclusion: Our study reveals a 22% prevalence of *S. aureus* colonization among healthy Congolese adults in an urban community. Moreover, the presence of multi-antibiotic resistant strains underscores the need for further investigation into nationwide prevalence, decolonization strategies, and their implications for the management of hospitalized patients.

Keywords: Bacteria, *Staphylococcus Aureus*; Carriage; Commensal; Pathogen; Republic of Congo; Central Africa

Introduction

Globally, *Staphylococcus aureus* is one of the leading causes of bacterial infections related mortality [1]. *S. aureus* is also an important pathogen identified in nosocomial infections caused by Gram-positive bacteria [2]. The recent increase in the incidence and severity of Staphylococcal infections has revived interest in studies assessing the burden of asymptomatic carriage of *S. aureus* in different communities [3]. This bacterial species is ranked first or second among bacterial pathogens responsible for bloodstream infections, pneumonia and complicated skin and soft tissue infections [4,5]. These infections commonly arise from pre-existing asymptomatic colonization. The known sites of *S. aureus* colonization are the nostrils, mouth, skin, and gastrointestinal tract [6-8]. It is estimated that up to 30% of the human population is colonized by *S. aureus*, including 50% of adults presenting persistent or intermittent carriage [9,10]. Given the risk of progression from colonisation to infection, decolonization or eradication of carriage prior to an intervention is common in clinical practice for prevention of *S. aureus* related sepsis.

Importantly, several circulating strains of *S. aureus* have developed resistance to commonly used antimicrobials, a phenomenon closely linked to their inappropriate usage [2]. Managing infections caused by resistant *S. aureus* therefore remains a major challenge for healthcare systems [11]. Severe skin and soft tissue infection, the most common expression of *S. aureus* infection in the community

setting, is strongly associated with the Panton Valentine Leukocidin (PVL), a virulence factor independent of methicillin resistance: both methicillin-resistant and methicillin-sensitive strains of *Staphylococcus aureus* [MRSA and MSSA] can produce PVL [12,13]. To identify the reservoir of *S. aureus* infection in the general population, epidemiological investigations involving asymptomatic carriers of *S. aureus* are of interest. Indeed, colonization has been shown to represent a reservoir for pathogenic strains and/or a pre-infectious stage [3] as well as the starting point for the development of nosocomial infections by drug-resistant pathogens, a major cause of mortality worldwide [14].

Across Africa, the data on *S. aureus* colonisation remains scarce. In the Republic of Congo reports from hospital settings on *S. aureus* infections are limited, with prevalences ranging from 28% to 80% [15,16]. So far, no investigation in the community has been reported. The primary objective of this study was to determine *S. aureus* carriage among healthy Congolese adults, with a secondary aim to characterize molecular markers of antimicrobial resistance.

Materials and Methods

Study Population

This cross-sectional study was conducted from 1st March to 31st July 2022 in Brazzaville, the capital of the Republic of Congo. Participants were recruited from all three areas of Brazzaville, which include the nine districts of the

city: area 1 in south (Makélékélé, Bacongo, Madibou); area 2 in the center (Poto-Poto, Moungali and Mfilou) and area 3 in the north (Ouenzé, Talangai and Djiri) as shown in figure 1. As of 2023, the estimated population of the Republic of the Congo was 6,142,180 inhabitants, with the majority residing in urban areas such as Brazzaville, a densely populated city which hosts one-third of the Congolese popula-

tion [17]. Recruitment efforts included widespread distribution of flyers across Brazzaville, targeting locations such as universities, schools, civil society associations and NGOs. Participation was voluntary, and inclusion criteria required participants to be at least 18 years old. Pregnant women, individuals known to be HIV seropositive, and those with compromised immune systems were excluded from the study.




Figure 1: Brazzaville city localisation, study area circumscriptions

Patient Recruitment and Sample Collection

Eligible participants were recruited by trained personnel. Clinical (date of previous hospitalization, use of antibiotics, history of skin and/or soft tissue infection, smoking, use of hormone contraception for women, socio-demographic data (age, sex, residence, number of household members, contact with animals) were recorded at enrolment. While the nasal samples were collected by swabbing both nostrils of everyone with a sterile cotton swab, the oropharyngeal swab was collected from the same participant by dabbing the larynx behind the tongue. Each swab

was preserved in Stuart Amie transport solid medium (Oxoid, Brescia Italy: 202485200) and transferred immediately to the microbiology laboratory at room temperature (28°C).

Bacterial Culture and Identification of *S. Aureus* Strains

Conventional bacterial culture was performed within 2 hours of the laboratory receiving the swab. Swabs were inoculated onto sheep Columbia blood agar (CM0331B, Oxoid™, Germany) prepared 24 hours in advance by following the manufacturer's instructions. The in-

oculation onto sheep blood agar of both swabs collected from each participant were cultured on two separate plates and incubated at 37°C for 18 to 24 hours. *S. aureus* was identified on the basis of the colony morphology followed by catalase and coagulase activity by a Staphytest Plus latex agglutination test (Oxoid) or by rabbit plasma agglutination in tubes (Becton Dickinson & Co, Lane Santa Maria, Canada) when the Staphytest agglutination test provided ambiguous results.

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was performed using the disc diffusion method according to Clinical Laboratory Standards Institute (CLSI) guidelines [18]. Briefly, colonies of pure bacterial strains were suspended in sterile normal saline with a McFarland standard turbidity equivalent to 0.5, and streaked evenly onto Muller Hinton Agar (MHA, Oxoid, Strasbourg-France) plates. After allowing the plates to dry, the following antibiotic discs were placed onto the plate: Cefoxitin (30 µg), Azithromycin (15 µg), Erythromycin (15 µg), Tigecycline (30 µg), Linezolid (30 µg) and Vancomycin (10 µg). Plates were then incubated at 37°C for 18 to 24 hours. After the incubation, the inhibition diameters around each antibiotic disc were measured and interpreted as susceptible (S), intermediate (I) or resistant (R) in accordance with CLSI guidelines [18]. All isolates resistant to Vancomycin according to disk diffusion were re-tested using the gradient diffusion (E-TEST, bioMérieux, Marcy l'Étoile, France).

Molecular Testing for MRSA and PVL Strain Identification

DNA was extracted from pure colonies using 10% Chelex (Bio Rad; California, US). In a labelled 2-ml tube, an equal volume of pure bacterial suspension and 10% Chelex was incubated at 90°C for 1 hour. The tube was then centrifuged at 22,378 g, the supernatant was used for PCR.

For the conventional PCR (using the Red Taq Mix kit, Oxoid), different genes were targeted to confirm the positivity of the *S. aureus* using different primer pairs (supplementary table). Firstly, *S. aureus* species isolated by culture

were confirmed by conventional PCR amplification of the *nuc* gene as described [19]. For the identification of MRSA, we targeted the *mecA* gene, using the protocol described by Murakami et al [20]. For PVL detection, we used *lukS-PV* and *lukF-PV* [13]. For quality control of culture and PCR confirmation, we used *S. aureus* strain (ATCC 33591). Gel electrophoresis was undertaken on all PCR amplicons in parallel with the 1 kb ladder (ThermoFisher, Vilnius, Lithuania) which served as the rule to estimate the size of amplicons by using a 2% agarose gel and were visualized using the Gel Doc CZ instrument.

Data Analysis

Statistical analysis included descriptive analysis for calculation of percentage, frequency, mean and median values and 95% confidence interval (95% CI). Associations of socio-demographic and clinical variables to *S. aureus* colonization were evaluated with the Pearson Chi-square test and crude Odds Ratios were estimated to quantify effect of risk factors. GraphPad software (version 9) was used for data analysis. A P value ≤0.05 was considered significant.

Ethical Approval

The study obtained ethical approval from the independent institutional ethics committee of the Fondation Congolaise pour la Recherche Médicale under number 021-D/CIE/FCRM/2021. Prior to enrolment, participants provided written informed consent. Additionally, an administrative authorization was granted by the Ministry of Public Health.

Results

Socio-demographic Characteristics of the Recruited Participants

One hundred and seventy-five (175) participants were included in this study, of whom 35 (20%) were women. The median age was 26 years (range 23-29 years). Most of the participants were aged between 18 and 28 years (n=129, 73.7%). As shown in Table I, most of the participants were living in the area 1 (50.9%) following by area 2 with 42.3% and 6.9% for area 3.

Table 1: Socio-demographic characteristics of the study Congolese population and the prevalence of *S. aureus* colonization

Variables	Participants N=175	<i>S. aureus</i> colonisation	
		Positive %(N=39)	Negative%(N=136)
Age group by years (Median [IQ])	(26 [23-29])	--	--
18-28	129	20 (26)	80 (103)
29-39	25	28 (7)	72 (18)
≥40	21	29 (6)	71 (15)
Sex			
M	140	20 (28)	80 (112)
F	35	31 (11)	69 (24)
Location			
Area 1	89	21 (19)	79 (70)
Area 2	74	24 (18)	76 (56)
Area 3	12	17 (2)	83 (10)


Staphylococcus Aureus Prevalence

S. aureus was detected in 39 of the 175 participants, corresponding to an *S. aureus* colonization of 22%. Of the 39 participants colonized with *S. aureus*, a greater proportion of women were colonized (11/35, 31%) compared to 20% of men (28/140as, Table I). The highest rate of

S. aureus carriage was identified in the age group ≥40 years, accounting for 29% (6/21) (Table I).

S. aureus carriage according to sampling site was identified as follows: of the participants carrying *S. aureus*, 29/39 (74%) carried *S. aureus* only in the nostrils, 6/39 (15%) carried *S. aureus* only in the oropharynx and 4/39 (10%) were dual carriers of *S. aureus* (Figure 2).

S. aureus Colonisation sites among congolese population

**Figure 2:** *S. aureus* colonization prevalence by collection site, in the 39 patients who were found to be positive

Evaluation of Risk Factors Associated to *S. Aureus* Colonization

In Table II the risk factors associated to *S. aureus*

colonization were assessed. None of the variables was significantly associated with *S. aureus* colonization. No significant differences (p value ≤ 0.05) were observed for the risk factors assessed.

Table 2: Evaluation of risk factors associated to *S. aureus* colonization

Variables	All participants	<i>S. aureus</i> colonisation% (n)	OR (95% CI)	P-value
Age (years)				
18-28	129	20 (26)	Reference	-
29-39	25	28 (7)	1.54 (0.602-3.89)	0.425
≥ 40	21	29 (6)	1.58 (0.55- 4.36)	0.394
Sex				
M	140	20 (28)	Reference	-
F	35	31.4 (11)	1.83 (0.83 – 4.24)	0.173
Smoking				
No	166	23 (38)	Reference	-
Yes	9	11 (1)	0.42 (0.05-3.47)	0.421
Antibiotics consumption within last three months				
No	112	22 (25)	Reference	-
Yes	63	22 (14)	1.22 (0.58-2.55)	0.592
Contact with animal				
No	145	25 (36)	Reference	-
Yes	30	10 (3)	0.33 (0.09-1.17)	0.08
Contact with bush meat				
No	168	21 (36)	Reference	-
Yes	7	43 (3)	2.75 (0.58-12.8)	0.198

Antibiotic Resistance Rates

In this study, a prevalence of 10% (4/39) of isolates carrying the *mecA* gene (MRSA) and a prevalence of 23% (9/39) of isolates carrying the PVL gene were reported. It has been found 5% (2/39) of these strains were simultaneously PVL and *mecA* positive. These two strains were isolated from men aged of 24 and 26 years old respectively who lived in the same neighborhood; Mougali, a densely populated area.

Single, dual and multi-antibiotic resistances were common and of seven antibiotics tested, there was no resis-

tance to tigecycline. Cefaclor had highest resistance rates (26%) expressed by the isolates tested, followed by Azithromycin and Erythromycin (21% each) with resistance rates of up to 20%. Although most of these strains presented a high level of resistance to the antibiotics tested, however some of them were effective on *S. aureus*, such as Cefoxitin (15%) and Vancomycin (13%) with a resistance rate of less than 16%, as shown in Table III. The comparison of the rate of resistance between MRSA and MSSA showed that MRSA strains were susceptible to almost all the antibiotics tested in this study. Methicillin-sensitive *S. aureus* (MSSA) presented an important resistance phenotype. Interestingly, none

of the PVL+ MRSA strains were resistant to any of the test-

ed antibiotics. One of the PVL-negative MRSA strain was resistant to only one antibiotic which is Cefoxitin.

Table 3: Antibiotic resistance rate and virulence expression of *S. aureus* strains

Antibiotics	PVL+ (n=9)		PVL- (n=30)		Total (n=39)n (%)
	<i>mecA</i> + (MRSA) (n=2)	<i>mecA</i> - (MSSA) (n=7)	<i>mecA</i> + (MRSA) (n=2)	<i>mecA</i> - (MSSA) (n=28)	
AZM	0	0	0	8 (29%)	8 (21%)
FOX	0	2 (29%)	1 (50%)	3 (11%)	6 (15%)
E15	0	0	0	8 (29%)	8 (21%)
TGC	0	0	0	0	0
LZD	0	1 (14%)	0	6 (21%)	7 (18%)
VA	0	0	0	5 (18%)	5 (13%)

AZM = Azithromycin; E15 = Erythromycin; CRO = Ceftriaxone; TGC = Tygecyclin; LZD = Linezolid; VA = Vancomycin

Resistance Rate Between Antibiotics Users and Non-Users

The prevalence of antibiotic resistance between participants who had used antibiotics within the last three months, and those who have not used, was investigated

(Table IV). An increase in resistance rates of *S. aureus*, isolated from participants who had not used antibiotics in the last three months, to three specific antibiotics (CC2, LZD and VA) was observed ($P= 0.03$; 0.001 and 0.001 respectively). No difference was observed with other antibiotics whatever the study group.

Table 4: Resistance rate between antibiotics users and non-users

Antibiotics	Overall rate of <i>S. aureus</i> resistance % (n)	Resistance rate of strains from antibiotics users within the last 3 months % (n)	Resistance rate of strains from non-antibiotic users in the last 3 months % (n)	P. Value
AZM	21 (8/39)	50 (4/8)	50 (4/8)	1.00
FOX	15 (6/39)	50 (3/6)	50 (3/6)	1.00
E15	21 (8/39)	38 (3/8)	62 (5/8)	0.80
TGC	0	0	0	--
LZD	18 (7/39)	0	100 (7/7)	0.001*
VA	13 (5/39)	0	100 (5/5)	0.001*

Discussion

This study has several important findings. This is the first study of *S. aureus* colonization in healthy Congolese adults from the urban community. It shows a high prevalence (22%) *S. aureus* carriage and a high proportion of MRSA (15%). These findings could have significant im-

pact on management of hospitalized patients for elective or emergency surgical procedures where preoperative decolonization is important for preventing *S. aureus* infection and requires appropriate use of specific targeted antibiotics. Whilst these results provide baseline data for future investigations, further studies are required to ascertain country-wide prevalence, decolonization and impact on manage-

ment of hospitalized patients.

Colonization by *S. aureus* represents a potential risk for the development of subsequent infections [21]. There is a paucity of available data in the Central Africa region, but the prevalence of 22% *S. aureus* carriage in healthy Congolese participants in this study is lower compared to that reported by Schaumburg *et al.*, 2013 [22] in Gabonese population showing the prevalence of 40% and 42%, after one month delivery, of *S. aureus* carriage respectively from mothers and their children. Indeed prevalence from this was higher compared to what reported from DRC at 13.3% from population in the community [23]. Nasal carriage has been shown to be the main reservoir involved in human-to-human transmission of *S. aureus* in hospitals, as well as in the community, and is also the main risk factor for infection, since colonization may be a prerequisite for *S. aureus* infection [24]. *S. aureus* infections in humans are most often due to the bacteria present at the site of colonization [25]. In the present study, it is important to note that in the present study most represented gender was male.

More importantly, of the 39 *S. aureus* carriers detected in this study, 75% were nasal carriers, only 15% were oropharyngeal carriers and the remaining 10% were carriers in both sites. These results suggest that nasal colonization is the main site for *S. aureus* colonization in the community in the Republic of Congo, as demonstrated by Von. Eiff *et al.*, 2001 [25], who reported that 86% of *S. aureus* strains collected from blood and nasal have identical clones using the Pulsed-Field Gel Electrophoresis method. It is therefore important to control nasal carriage of *S. aureus* in order to reduce the incidence of *S. aureus* infections in both community and nosocomial settings.

Another parameter that needs to be considered in interpretation of the results is the age of the participants. It has been reported that *S. aureus* colonization rates are high immediately after birth, compared with the elderly in whom colonization rates appear to decrease over time [26,27].

Although in the present study in Brazzaville (RoC), the age group of 18-28 years was the most represented, *S. aureus* colonization was reported to be the highest in the adult age group ≥ 40 years including more but not signifi-

cant nasal *S. aureus* infection.

In this study, a prevalence of 23% of PVL+ among *S. aureus* isolates was reported in the MRSA and MSSA groups. It is lower than those from Saudi Arabia and Tunisia with 30% and 41%, respectively [10,28]. Among PVL+ *S. aureus*, a prevalence of 22% (2/9) MRSA was identified, similar results were observed also in Tunisia [29]. Carriage of this toxin within the Congolese community poses a threat, as PVL has been shown to reduce the effectiveness of the immune system by killing neutrophils and other immune cells [30]. In addition, PVL+ isolates are particularly difficult to treat if nasal carriage develops into infection.

The molecular profile of only two PVL+ MRSA strains identified in the present study were sensitive to all tested antibiotics. In contrary to the work reported by Sadar *et al.*, 2022 showing that PVL+ MRSA strains presenting higher resistance rate vs PVL+ MSSA strains [31]. Discrepancies in findings may be attributed to sample size, type of sample, geographical area, methodology used and the prevalence of strains with specific antibiogram profile. In comparison with the results of Baran *et al.*, 2010 [32] who detected PVL only among MRSA isolates in Turkey and Santosaningsih *et al.*, 2016 who reported positive PVL only among MSSA isolates in Indonesia [33], in the current study the PVL in both MSSA and MRSA isolates were detected, which represents a major public health problem for the Congolese population.

A prevalence of 10% of MRSA isolates was found in this study. In DRC, a prevalence of (33%) MRSA isolates was reported in healthy participants and these isolates were significantly resistant to many more classes of antibiotics [23]. At least 20% of MSSA isolates were resistant to azythromycin, and erythromycin indicating that these antibiotics are less effective in therapy against *S. aureus*.

Malaria is a major cause of hospitalization and in-hospital mortality among children in Africa [34], and in the Republic of Congo the disease is endemic, where treatment is almost always combined with at least one antibiotic tested in this study. The high level of resistance to these antibiotics (Azythromycin and Erythromycin) may be linked to their frequent use in the treatment of malaria. Of the 6 antibiotics used, only one, Tygecycline, was effective

on all *S. aureus* isolates tested. This antibiotic must be used with care, as it conserved its effectivity among all the antibiotics we have used against *S. aureus* isolates. Unfortunately, no strong legislation in the Congo controls the use or sale of antibiotics in the community. Antibiotic resistance is a global public health problem. These results underline the importance of adopting control measures against the misuse of antibiotics.

Limits have been identified in this study. First, the sample collection time was very short. Consequently, the dynamics of *S. aureus* isolates over a longer period like 12 months could not be assessed. Second, a multilocus sequence typing (MLST) was not performed, so the association between MRSA or MSSA and circulating MLST could not be established. Third, the use of selective media would have increased the detection and therefore colonization rates of *S. aureus* in addition to the small selection of antimicrobial. Fourth, rural or semi-urban areas were not considered in this study. Differences in the profile of these ecosystems are also important for understanding the mechanism of resistance in different regions. These shortcomings should be considered in future studies to provide more information on *S. aureus* colonization in the community.

Conclusion

A prevalence of 22%, of *S. aureus* carriage was reported including the presence of MRSA isolates (10 % of the *S. aureus* found in carriers). Among *S. aureus* isolates, 23% of isolates tested carried the PVL gene. The profile of PVL positive MRSA strains was identified, showing the importance of investing in intensive surveillance of *S. aureus* in

the community.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Funding

This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, grant 404893180 to FS and FN). This work received support from the Central Africa Clinical Research Network, CANTAM (EDCTPCSA2020NoE3100) and from the Central Africa Humboldt research Hub (HRH-Coca) funded by the Alexander von Humboldt foundation. CCMM was supported by the Fondation Merieux.

Authors' Contributions

Study design: FN, FS. Implementation of the study: CCMM, JNGL, NM, KB, AMM. Analysis of the results: CCMM, CJV, RA, LE. All authors contributed to writing the manuscript, read and approved the final version.

Acknowledgements

The authors thank all the participants for their co-operation. We appreciate Ms Providence SITA for her technical assistance in the laboratory. The funders did not play a role in the design of the study, collection, analysis, and interpretation of data, as well as the writing of the manuscript.

References

1. Piewngam P, M Otto (2024) *Staphylococcus aureus* colonisation and strategies for decolonisation. *Lancet Microbe*.
2. Deyno S, et al. (2017) Antimicrobial resistance profile of staphylococcus aureus isolates isolated from ear discharges of patients at University of Hawassa comprehensive specialized hospital. *BMC Pharmacol Toxicol*, 18: 35.
3. Pires FV, et al. (2014) Nasal carriage of *Staphylococcus aureus* in Botucatu, Brazil: a population-based survey. *PLoS One*, 9: e92537.
4. Bartoloni A, et al. (2013) Low prevalence of methicillin-resistant *Staphylococcus aureus* nasal carriage in urban and rural community settings in Bolivia and Peru. *Int J Infect Dis*, 17: e339-42.
5. Riya Mukherjee AP, Ramendra Pati Pandey, Vethakkani Samuel Raj (2021) Antimicrobial Resistance in *Staphylococcus aureus*. *IntechOpen*.
6. Ndhlovu GON, et al. (2021) Molecular epidemiology of *Staphylococcus aureus* in African children from rural and urban communities with atopic dermatitis. *BMC Infect Dis*, 21: 348.
7. Onanuga A, TC Temedie (2011) Multidrug-resistant intestinal *Staphylococcus aureus* among self-medicated healthy adults in Amassoma, South-South, Nigeria. *J Health Popul Nutr*, 29: 446-53.
8. Schaumburg F, et al. (2014) Transmission of *Staphylococcus aureus* between mothers and infants in an African setting. *Clin Microbiol Infect*, 20: O390-6.
9. Laux C, A Peschel, B Krismer, (2019) *Staphylococcus aureus* Colonization of the Human Nose and Interaction with Other Microbiome Members. *Microbiol Spectr*, 7.
10. Bazzi AM, et al. (2015) Prevalence of Panton-Valentine leukocidin-positive methicillin-susceptible *Staphylococcus aureus* infections in a Saudi Arabian hospital. *J Infect Public Health*, 8: 364-8.
11. Chen X, et al. (2015) Rapid detection of *Staphylococcus aureus* in dairy and meat foods by combination of capture with silica-coated magnetic nanoparticles and thermophilic helicase-dependent isothermal amplification. *J Dairy Sci*, 98: 1563-70.
12. Leistner R, et al. (2022) Skin Infections Due to Panton-Valentine Leukocidin-Producing *S. Aureus*. *Dtsch Arztebl Int*, 119: 775-84.
13. Shallcross LJ, et al. (2013) The role of the Panton-Valentine leukocidin toxin in staphylococcal disease: a systematic review and meta-analysis. *Lancet Infect Dis*, 13: 43-54.
14. Flora Cruz-López LVT, Rayo Morfin-Otero, Adrián Martínez-Meléndez, Adrián Camacho-Ortiz, Eduardo Rodríguez-Noriega, Elvira Garza-González (2020) Dynamics of colonization in patients with health care-associated infections at step-down care units from a tertiary care hospital in Mexico. *American Journal of Infection Control*, 48: 1329-35.
15. Rachel Moyon EN, Gabriel Ahombo, Nina Esther Ontsira, Claudette Gatsele Yala, Obengui, Simon Charles Kobawila, Delphin Louembe (2014) Comparative Study to Amino Glycoside Antibiotics Resistance of *Staphylococci* Strains Isolated from Wounds at Brazzaville. *International Journal of Science and Research (IJSR)* 6.
16. Ahombo Gabriel MR, Baloki Ngoulou Tarcisse, Kayath Aimé Christian, Ontsira Ngoyi Nina Esther (2019) Genetic Determinism in Community *Staphylococcus* and Methicillin-Resistant Clinics in Brazzaville, Republic of Congo. *International Journal of Innovative Research in Medical Science (IJIRMS)*, 4: 454-9.
17. Institut National de la Statistique, R.o.C. (2023) Communiqué relatif à la publication des résultats préliminaires du RGPH-5. Google.
18. (CLSI), C.L.S.I. (2020) Performance standards for antimicrobial susceptibility testing.
19. Brakstad OG, K Aasbakk, JA Maeland (1992) Detection of *Staphylococcus aureus* by polymerase chain reaction amplification of the nuc gene. *J Clin Microbiol*, 30: 1654-60.
20. Murakami K, et al. (1991) Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. *J Clin Microbiol*, 29: 2240-4.

21. Schaumburg F, et al. (2014) New epidemiology of *Staphylococcus aureus* infection in Africa. *Clin Microbiol Infect*, 20: 589-96.
22. F Schaumburg, ASA, G Mombo-Ngoma, H Kaba, RM Zoleko, DA Diop, JR Mackanga, et al. (2013) Transmission of *Staphylococcus aureus* between mothers and infants in an African setting. *Clinical Microbiology and Infection*, 20: O390-6.
23. Phaku P, et al. (2016) Unveiling the molecular basis of antimicrobial resistance in *Staphylococcus aureus* from the Democratic Republic of the Congo using whole genome sequencing. *Clin Microbiol Infect*, 22: 644 e1-5.
24. Miller M, et al. (2009) *Staphylococcus aureus* in the community: colonization versus infection. *PLoS One*, 4: e6708.
25. Christof Von Eiff KB, Konstanze Machka, Holger Stammer, Georg Peters, (2001) Nasal Carriage as a Source Of *Staphylococcus Aureus* Bacteremia. *The New England Journal of Medicine*, 344: 11-6.
26. Kinabo GD, et al. (2013) Dynamics of nasopharyngeal bacterial colonisation in HIV-exposed young infants in Tanzania. *Trop Med Int Health*, 18: 286-95.
27. Olalekan AO, et al. (2012) Clonal expansion accounts for an excess of antimicrobial resistance in *Staphylococcus aureus* colonising HIV-positive individuals in Lagos, Nigeria. *Int J Antimicrob Agents*, 40: 268-72.
28. Chaouch C, KS Tilouche L, Ketata S, Bouallegue O, Boujaafar N, (2015) Pantone-Valentine leukocidin-positive osteoarticular infections. *Médecine et Santé Tropicales*, 25: 184-8.
29. Dohin B, GY Kohler R, Lina G, Vandenesch F, Vanhems P, et al. (2007) Pediatric bone and joint infections caused by Pantone-Valentine leukocidin positive *Staphylococcus aureus*. *Pediatric Infection Disease Journal*, 26.
30. Genestier AL, et al. (2005) *Staphylococcus aureus* Pantone-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. *J Clin Invest*, 115: 3117-27.
31. Sadat A, et al. (2022) Prevalence and Characterization of PVL-Positive *Staphylococcus aureus* Isolated from Raw Cow's Milk. *Toxins (Basel)*, 14.
32. Baran CB, et al. (2010) [Investigation of Pantone-Valentine leukocidin gene, SCCmec gene cassette types and genotypes of methicillin-resistant *Staphylococcus aureus* strains isolated from outpatients]. *Mikrobiyol Bul*, 44: 533-45.
33. Santosaningsih D, et al. (2016) Characterisation of clinical *Staphylococcus aureus* isolates harbouring mecA or Pantone-Valentine leukocidin genes from four tertiary care hospitals in Indonesia. *Trop Med Int Health*, 21: 610-8.
34. Kazembe LN, I Kleinschmidt, BL Sharp (2006) Patterns of malaria-related hospital admissions and mortality among Malawian children: an example of spatial modelling of hospital register data. *Malar J*. 5: 93.

Submit your manuscript to a JScholar journal and benefit from:

- ¶ Convenient online submission
- ¶ Rigorous peer review
- ¶ Immediate publication on acceptance
- ¶ Open access: articles freely available online
- ¶ High visibility within the field
- ¶ Retaining the copyright to your article

Submit your manuscript at
<http://www.jscholaronline.org/submit-manuscript.php>